Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OPRK1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal, Intraperitoneal, Parenteral
01
Overview
OPRK1 siRNA is a small interfering RNA designed to silence the expression of the kappa opioid receptor (OPRK1). In preclinical research involving breast cancer models, OPRK1 has been identified as a promoter of cell migration and viability, showing significant overexpression in malignant cells compared to normal mammary epithelial cells. The therapeutic mechanism of OPRK1 siRNA involves the knockdown of OPRK1 mRNA, which subsequently leads to the downregulation of mesenchymal markers such as N-cadherin, Snail, MMP2, and Vimentin, while increasing the expression of the epithelial marker E-cadherin. This shift effectively inhibits the epithelial-mesenchymal transition (EMT) and suppresses cancer cell migration. Additionally, OPRK1 knockdown has been shown to inactivate the PI3K/AKT signaling pathway, and its combination with AKT inhibitors has been proposed as a potential therapeutic strategy for breast cancer.
- Other names
- OPRK1 small interfering RNAOPRK-1 small interfering RNAOPRK 1 small interfering RNAkappa opioid receptor siRNAsi-OPRK1si-OPRK-1si-OPRK 1
02
Targets
KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on OPRK1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OPRK1 siRNA.